Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsUnitedHealthcare Duvyzat Prior Auth Policy | OpenP…
    Ask Trek AI about this page
    CurrentUnitedHealthcarePolicy N/A

    Duvyzat (givinostat) Coverage Criteria

    Customize your policy alerts

    Sign up for all UnitedHealthcare policy alerts

    Know when UnitedHealthcare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs UnitedHealthcare prior authorization and reauthorization for Duvyzat oral suspension for Duchenne muscular dystrophy in patients 6 years of age or older, subject to stated clinical criteria, benefit terms, and applicable utilization-management processes.

    Policy Summary
    PayerUnitedHealthcare
    PolicyDuvyzat (givinostat) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAdministrative/reference update
    Effective DateOctober 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionFor reauthorization, provide documentation of a positive clinical response to Duvyzat therapy.
    SourceLink
    POLICY UPDATE CHANGES

    The policy underwent an annual review with no changes to the coverage criteria, and the reference information was updated.

    6+ yearsMinimum age
    12 monthsInitial authorization
    Positive responseReauthorization
    PA/notificationUtilization management

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    May apply
    Supply limits

    Coverage Criteria

    Initial Authorization

    Covered when all of the following are met:

    Initial authorization criteria

    • Diagnosis: The patient has a diagnosis of Duchenne muscular dystrophy.
    • Age: The patient is 6 years of age or older.>= 6 years

    Reauthorization

    Covered when the following criterion is met:

    Reauthorization criterion: Documentation demonstrates a positive clinical response to Duvyzat therapy.

    Authorization will be issued for 12 months.

    Authorization and Documentation Requirements

    Prior Authorization

    Obtain initial authorization

    Duvyzat is managed under the Prior Authorization/Notification program. For initial authorization, document a diagnosis of Duchenne muscular dystrophy and confirm that the patient is 6 years of age or older.

    • Authorization is issued for 12 months.
    Prior Authorization

    Document response for reauthorization

    For reauthorization, provide documentation of a positive clinical response to Duvyzat therapy. Reauthorization is issued for 12 months.

    Documentation Required

    Document positive clinical response

    Policy Background

    Duvyzat (givinostat) is a histone deacetylase inhibitor indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older. This policy addresses UnitedHealthcare coverage for Duvyzat oral suspension under the Prior Authorization/Notification program, including initial treatment and continued therapy.

    Clinical and Pharmacologic Definitions

    DMD
    TermDMD
    DefinitionDuchenne muscular dystrophy
    Policy indicationDuchenne muscular dystrophy in patients 6 years of age and older
    Duvyzat Pharmacologic Class
    DrugDuvyzat (givinostat)
    Pharmacologic classHistone deacetylase inhibitor
    IndicationTreatment of Duchenne muscular dystrophy

    Initial Therapy

    Initial Therapy Criteria

    Initial authorization is covered when all of the following are met:

    Initial therapy criteria

    • Diagnosis: The patient has a diagnosis of Duchenne muscular dystrophy.
    • Age: The patient is 6 years of age or older.>= 6 years

    Continuation Therapy

    Continuation Therapy

    Reauthorization is covered when the following criterion is met:

    Positive clinical response: Documentation of a positive clinical response to Duvyzat therapy.

    Authorization will be issued for 12 months.

    Quantity and Supply Limits

    Quantity Limits
    DrugDuvyzat
    Supply limit statusSupply limits may be in place
    Potential restrictionDispensing may be subject to applicable supply limits
    Policy Summary
    PayerUnitedHealthcare
    PolicyDuvyzat (givinostat) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAdministrative/reference update
    Effective DateOctober 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionFor reauthorization, provide documentation of a positive clinical response to Duvyzat therapy.
    SourceLink
    On This Page
    Coverage CriteriaAuthorization and Documentation RequirementsPolicy BackgroundClinical and Pharmacologic DefinitionsInitial TherapyContinuation TherapyQuantity and Supply Limits

    Provide documentation demonstrating a positive clinical response to Duvyzat therapy when requesting reauthorization.

    Denial Risk

    Meet initial authorization criteria

    Initial authorization may be denied if the patient does not have a diagnosis of Duchenne muscular dystrophy or is younger than 6 years of age.

    • Required initial criteria: diagnosis of Duchenne muscular dystrophy and patient age of 6 years or older.
    Denial Risk

    Demonstrate positive response

    Reauthorization may be denied if documentation does not demonstrate a positive clinical response to Duvyzat therapy.